 Contrast-associated nephropathy ( CAN) is an extensively studied but equally controversial sequela of intravascular contrast use. Despite this , there is still significant debate about its definition and thus incidence , the impact of route of contrast administration , and ultimately , what constitutes appropriate clinical practice in light of risks. While guidelines can not replace clinical judgment , without consensus either enthusiastic withholding of contrast from necessary procedures or its administration despite increased risk may be deleterious to patient outcomes. This article reviews current literature on route-dependent risk and other interplaying factors impacting incidence of CAN..